Histopathological Spectrum and Short-Term Outcome of Treatment with Cyclophosphamide in Relapsing Steroid-Sensitive Nephrotic Syndrome

被引:1
|
作者
Bajeer, Irshad Ali [1 ]
Khatri, Sabeeta [1 ]
Tresa, Veena [1 ]
Hashmi, Seema [1 ]
Mubarak, Mohammed [2 ]
Lanewala, Ali Asghar [1 ]
机构
[1] Sindh Inst Urol & Transplantat, Dept Pediat Nephrol, Karachi, Pakistan
[2] Sindh Inst Urol & Transplantat, Dept Histopathol, Karachi, Pakistan
关键词
Relapsing steroid-sensitive nephrotic syndrome; Cyclophosphamide; MCD; FSGS; Mesangioproliferative glomerulonephritis (MesPGN); FOCAL SEGMENTAL GLOMERULOSCLEROSIS; CHILDREN; THERAPY;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To determine the short-term outcome of cyclophosphamide (CPO) course in children with relapsing steroid sensitive nephrotic syndrome (SSNS) with different histopathological lesions. Study Design: Descriptive, observational study. Place and Duration of Study: Pediatric Nephrology Department, Sindh Institute of Urology and Transplantation, Karachi, from January 2012 to December 2014. Methodology: All children with relapsing steroid-sensitive nephrotic syndrome, who underwent renal biopsy and received cyclophosphamide therapy, were included and followed up for 2 years. Histopathological features in renal biopsy, duration of treatment, duration of complete remission and complication frequency was noted. Results: Of the total 74 patients, 47 (63.5%) were males and 27 (36.5%) females. Median age with Interquartile range (IQR) at presentation was 5 years (4-7 years). Minimal change disease (MCD) was the most common histopathological diagnosis (n=54, 73%) followed by focal segmental glomerulosclerosis (FSGS) (n=13, 17.5%), mesangioproliferative glomerulonephritis (MesPGN) (n=6, 8.1%), IgA nephropathy (n=1, 1.4%). The median number of glomeruli included in each biopsy sample was 15. The median duration of treatment with CPO was 11 weeks (9 to 13 weeks), whereas the median duration of complete remission post-therapy was 13 months (7-23 months). A median timeframe of 17 months (13-24.2 months) lapsed between establishing the diagnosis of NS and initiating CPO treatment. Leucopenia was noted in six (8.1%) patients. Conclusion: The short-term outcome of relapsing SSNS can be improved with CPO and steroids, with minimum short-term side effects.
引用
收藏
页码:436 / 439
页数:4
相关论文
共 50 条
  • [1] Cyclophosphamide in steroid-sensitive nephrotic syndrome: outcome and outlook
    Udo Vester
    Birgitta Kranz
    Stephanie Zimmermann
    Peter F. Hoyer
    [J]. Pediatric Nephrology, 2003, 18 : 661 - 664
  • [2] Cyclophosphamide in steroid-sensitive nephrotic syndrome: outcome and outlook
    Vester, U
    Kranz, B
    Zimmermann, S
    Hoyer, PF
    [J]. PEDIATRIC NEPHROLOGY, 2003, 18 (07) : 661 - 664
  • [3] CYCLOPHOSPHAMIDE TREATMENT IN STEROID-SENSITIVE NEPHROTIC SYNDROME OF CHILDHOOD
    BARRATT, TM
    OSOFSKY, SG
    BERCOWSKY, A
    SOOTHILL, JF
    KAY, R
    [J]. LANCET, 1975, 1 (7898): : 55 - 58
  • [4] CONTROLLED TRIAL OF CYCLOPHOSPHAMIDE IN STEROID-SENSITIVE RELAPSING NEPHROTIC SYNDROME OF CHILDHOOD
    BARRATT, TM
    SOOTHILL, JF
    [J]. LANCET, 1970, 2 (7671): : 479 - &
  • [5] Treatment of steroid-sensitive nephrotic syndrome
    Srivastava, RN
    [J]. PEDIATRIC NEPHROLOGY, 2001, 16 (06) : 528 - 528
  • [6] Treatment of steroid-sensitive nephrotic syndrome
    Franke, I.
    [J]. MONATSSCHRIFT KINDERHEILKUNDE, 2009, 157 (03) : 226 - 234
  • [7] Iron homeostasis in relapsing steroid-sensitive nephrotic syndrome of childhood
    Kemper, MJ
    Bello, AB
    Altrogge, H
    Timmermann, K
    Ludwig, K
    Müller-Wiefel, DE
    [J]. CLINICAL NEPHROLOGY, 1999, 52 (01) : 25 - 29
  • [8] Is biopsy required in steroid-sensitive prior to cyclophosphamide nephrotic syndrome?
    Stadermann, MB
    Lilien, MR
    van de Kar, NCAJ
    Monnens, LAH
    Schröder, CH
    [J]. CLINICAL NEPHROLOGY, 2003, 60 (05) : 315 - 317
  • [9] Update on the treatment of steroid-sensitive nephrotic syndrome
    Zotta, Federica
    Vivarelli, Marina
    Emma, Francesco
    [J]. PEDIATRIC NEPHROLOGY, 2022, 37 (02) : 303 - 314
  • [10] PHARMACOKINETICS OF ORAL CYCLOPHOSPHAMIDE IN CHILDHOOD STEROID-SENSITIVE NEPHROTIC SYNDROME
    Kerb, R.
    Vester, U.
    Hofmann, U.
    Schaeffeler, E.
    Hoyer, P. F.
    Schwab, M.
    Kranz, B.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S23 - S23